TECHWIRE 30
(CIX: WRAL30)  981.51  up arrow+2.42  (0.25 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Apple)  517.96  down arrow-3.72  (-0.71 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: QUINTILES)  50.67  up arrow+0.12  (0.24 %)  Updated: 06:40 PM EDT, Apr 15 2014
(OP: BASF SE)  106.59  down arrow-1.11  (-1.03 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: BioCryst)  8.33  up arrow+0.08  (0.97 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: BioDelivery)  7.13  down arrow-0.05  (-0.7 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: CEMP)  8.73  down arrow-0.12  (-1.36 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Cisco Systems)  22.89  up arrow+0.04  (0.18 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  55.51  up arrow+0.59  (1.07 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: DARA)  2.50  down arrow-0.1  (-3.85 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: EMC CORPORATION)  26.92  up arrow+0.17  (0.64 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: Extreme Networks)  5.65  up arrow+0.03  (0.53 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Facebook)  59.09  up arrow+0.2  (0.34 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: GLAXOSMITHKLINE)  52.32  up arrow+0.48  (0.93 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: GOOG)  536.44  up arrow+3.92  (0.74 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: IBM)  197.02  down arrow-0.75  (-0.38 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NY: LH)  101.56  up arrow+0.81  (0.8 %)  Updated: 06:40 PM EDT, Apr 15 2014
(OP: Lenovo Group)  23.40  down arrow-0.9  (-3.7 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: MRK)  56.05  up arrow+0.48  (0.86 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: Microsoft Corp)  39.75  up arrow+0.57  (1.45 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: NetApp)  37.00  up arrow+0.21  (0.56 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: NOVARTIS AG)  83.79  down arrow-0.04  (-0.05 %)  Updated: 06:40 PM EDT, Apr 15 2014
(OP: Novozymes A/S)  43.66  up arrow+0.86  (2.01 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: PFIZER)  29.89  up arrow+0.02  (0.07 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: Pozen)  8.47  down arrow-0.18  (-2.08 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NY: RED HAT)  50.10  up arrow+0.27  (0.54 %)  Updated: 06:40 PM EDT, Apr 15 2014
(NQ: BBRY)  7.21  up arrow+0.07  (0.98 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: Salix)  98.19  up arrow+0.49  (0.5 %)  Updated: 08:10 PM EDT, Apr 15 2014
(NQ: SQI)  25.03  down arrow-0.11  (-0.44 %)  Updated: 08:10 PM EDT, Apr 15 2014

Posts tagged “Salix”

Updated February 27

Premium Lock Salix strikes $12M licensing deal for bowel prep drug

Salix Raleigh-based Salix Pharmaceuticals, which focuses on gastrointestinal treatments, is adding another product to its lineup. Salix is committing $12 million plus royalties to RedHill Biopharma for a bowel prep drug.

February 25

Premium Lock Salix prevails in $150M suit filed by drug partner

Salix In a legal fight dating to 2011, Raleigh-based Salix Pharmaceuticals has won a jury decision that throws out a lawsuit filed against it by drug partner Napo Pharmaceuticals.

January 30

Premium Lock FDA accepts new drug filing for Salix rectal inflammation drug

Salix A proposed treatment for a difficult to threat form of rectal inflammation licensed by Salix Pharmaceuticals is moving closer to approval by the FDA.

Updated January 14

Premium Lock Expanding Salix sales force expected to grow drug sales to $1.6B in 2014

Salix Salix Pharmaceuticals expects it will reach $1.6 billion in total product revenue this year. WRALtechWire Insiders can read more details on the gastrointestinal pharma's projections following the close of its $2.8 billion acquisition of Santarus as its stock hits a new record high.

January 3

Premium Lock Salix closes on $2.6B deal for San Diego pharma Santarus

Salix, a specialty pharmaceutical company focused on gastrointestinal treatments, said it will acquire all of the outstanding common stock of Santarus at the price of $32 per share, a 37.9 premium over the company's Thursday closing price of $23.20

Salix Salix

Updated November 7, 2013

Premium Lock Salix to acquire San Diego pharma Santarus for $2.6B

Salix, a specialty pharmaceutical company focused on gastrointestinal treatments, said it will acquire all of the outstanding common stock of Santarus at the price of $32 per share, a 37.9 premium over the company's Thursday closing price of $23.20

Salix Salix

August 8, 2013

Premium Lock Salix CEO Logan talks about M&A strategy

Salix Even though Salix Pharmaceuticals has diversified its portfolio of gastrointestinal drug treatments, CEO Carolyn Logan says Salix is always looking for deals. Read what she has to say about Salix's acquisition strategy.

Updated June 11, 2013

Premium Lock Salix constipation drug Relistor to go before FDA advisory panel

Salix Salix Pharmaceuticals' (NASDAQ:SLXP) constipation drug Relistor, which failed to win regulatory approval last year, will be up for review by a FDA advisory committee.

May 22, 2013

Premium Lock Salix rectal inflammation drug shows positive clinical trial results

Salix Salix Pharmaceuticals' topical foam to treat rectal inflammation could be filed for approval with the Food and Drug Administration by the end of September.

Updated May 10, 2013

Premium Lock Prescription growth lifts Salix's 1Q sales

Salix First quarter sales of Salix Pharmaceuticals' top drug, Xifaxan, increased 18 percent year over year. Read more about the company's performance.

Updated May 10, 2013

Premium Lock FDA makes Salix wait on constipation drug; company says no new trials needed

Salix The FDA said it needed more data to approve expanded use of Salix Pharmaceutical's constipation drug Relistor. Read why Salix thinks it has enough information.

Updated March 6, 2013

Premium Lock Salix CEO gears for federal probe that could go on for 'quite some time'

Salix Carolyn Logan, chief executive officer at Raleigh-based Salix pharmaceuticals, and the company are gearing up for what could be a lengthy federal investigation into its marketing practices.

Updated February 15, 2013

Premium Lock Feds subpoena Salix, ask about drug promotion practices

Salix Federal prosecutors have questions about how Salix Pharmaceuticals (NASDAQ:SLXP) sells and promotes its drugs, including its top-selling product Xifaxan.

January 3, 2013

Premium Lock Drug approval sends Salix shares up nearly 5%

Salix Shares in Salix Pharmaceuticals rose nearly 5 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.

January 2, 2013

Premium Lock FDA approves new Salix drug to treat AIDS-related diarrhea

Salix Shares in Salix Pharmaceuticals rose more than 3 percent Wednesday on news that the FDA had approved its new drug for the treatment of AIDS-related diarrhea.

November 8, 2012

Premium Lock Earnings: Salix; PowerSecure; Pozen; BioCryst

Bulldog Inside the Bulldog Blog: Revenues up at Salix; record revenues for PowerSecure; Pozen cuts losses; net loss declines at Biocryst;

Updated October 23, 2012

Premium Lock Raleigh drug firm Salix sponsors documentary on liver disease

Salix Pharmaceuticals and the American Liver Foundation back a new documentary about hepatic encephalopathy, or HE, which was directed by Academy Award winner Cynthia Wade.

Salix backs "HE" documentary Salix backs "HE" documentary

September 5, 2012

Premium Lock FDA again delays Salix gastrointestinal drug

Salix The FDA has again delayed an approval decision for a new diarrhea drug from Salix Pharmaceuticals.

August 9, 2012

Premium Lock Salix pays $10M upfront for possible treatment of Crohn's Disease

Salix The Raleigh-based pharmaceutical firm licenses rights to an extended release version of the drug Rifaximin that targets gastrointestinal and respiratory ailments.

August 9, 2012

Premium Lock Earnings: Salix, Cempra, Targacept, Cornerstone

Earnings Four North Carolina-based life science firms report an overall mixed bag of results, but Raleigh-based Salix reports huge jump in sales.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll